Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 163, Issue 4, 2001, Pages 887-891

  Nagaya, Noritoshi ^a   Uematsu, Masaaki ^a   Oya, Hideo ^a   Sato, Nagato ^a   Sakamaki, Fumio ^a   Kyotani, Shingo ^a   Ueno, Kazuyuki ^a   Nakanishi, Norifumi ^a   Yamagishi, Masakazu ^a   Miyatake, Kunio ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CITRULLINE; NITRIC OXIDE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; EXERCISE; FEMALE; HEMODYNAMICS; HUMAN; HYPOTENSION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL;

EID: 0035060156     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.163.4.2007116     Document Type: Article

References (27)

1. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
2. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension
3. Inhaled nitric oxide for the adult respiratory distress syndrome
4. Improvement in exercise capacity with nitric oxide inhalation in patients with precapillary pulmonary hypertension
5. The L-arginine-nitric oxide pathway
6. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure
7. Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats
8. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension
9. Primary pulmonary hypertension: A national prospective study
10. Blood oxygen measurements in the assessment of intracardiac left to right shunts: A critical appraisal of methodology
11. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension
12. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension
13. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension
14. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans
15. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans
16. Effect of L-arginine on coronary endothelial function in cardiac transplant recipients
17. Improvement of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive heart failure
18. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)
19. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): Results of a randomized trial
20. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
21. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
22. Orally active prostacyclin analogue in primary pulmonary hypertension
23. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension
24. Maximal perfusion of skeletal muscle in man
25. Correction of endothelial dysfunction in chronic heart failure: Additional effects of exercise training and oral L-arginine supplementation
26. Increased exercise ventilation in patients with chronic heart failure: Intact ventilatory control despite hemodynamic and pulmonary abnormalities
27. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension